Literature DB >> 17464448

Using blood brain barrier disruption by methamphetamine for drug delivery.

R E Kast.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17464448     DOI： 10.1007/s11060-007-9389-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  6 in total

1.  Alterations in blood-brain barrier function by morphine and methamphetamine.

Authors:  Hari Shanker Sharma; Syed F Ali
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

Review 2.  Causes and consequences of methamphetamine and MDMA toxicity.

Authors:  Maria S Quinton; Bryan K Yamamoto
Journal:  AAPS J       Date:  2006-05-12       Impact factor: 4.009

3.  Methamphetamine induces AP-1 and NF-kappaB binding and transactivation in human brain endothelial cells.

Authors:  Y W Lee; B Hennig; J Yao; M Toborek
Journal:  J Neurosci Res       Date:  2001-11-15       Impact factor: 4.164

4.  Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting.

Authors:  Nancy D Doolittle; David M Peereboom; Gregory A Christoforidis; Walter A Hall; Diane Palmieri; Penelope R Brock; Kathleen C M Campbell; D Thomas Dickey; Leslie L Muldoon; Brian Patrick O'Neill; Darryl R Peterson; Brad Pollock; Carole Soussain; Quentin Smith; Rose Marie Tyson; Edward A Neuwelt
Journal:  J Neurooncol       Date:  2006-07-21       Impact factor: 4.130

5.  High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus.

Authors:  John F Bowyer; Syed Ali
Journal:  Synapse       Date:  2006-12-01       Impact factor: 2.562

6.  Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.

Authors:  Sandeep Kunwar; Michael D Prados; Susan M Chang; Mitchel S Berger; Frederick F Lang; Joseph M Piepmeier; John H Sampson; Zvi Ram; Philip H Gutin; Robert D Gibbons; Kenneth D Aldape; David J Croteau; Jeffrey W Sherman; Raj K Puri
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544
  6 in total
  7 in total

1.  Morphine facilitates doxorubicin penetration in the central nervous system: a new prospect for therapy of brain tumors.

Authors:  Iacopo Sardi
Journal:  J Neurooncol       Date:  2011-01-14       Impact factor: 4.130

2.  Morphine modulates doxorubicin uptake and improves efficacy of chemotherapy in an intracranial xenograft model of human glioblastoma.

Authors:  Martina da Ros; Anna Lisa Iorio; Dario Consolante; Francesco Cardile; Monica Muratori; Ornella Fantappiè; Maurizio Lucchesi; Milena Guidi; Claudio Pisano; Iacopo Sardi
Journal:  Am J Cancer Res       Date:  2016-02-15       Impact factor: 6.166

3.  Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib.

Authors:  Richard E Kast; Daniele Focosi
Journal:  Transl Oncol       Date:  2010-02       Impact factor: 4.243

Review 4.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

Review 5.  Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma.

Authors:  R E Kast
Journal:  J Neurooncol       Date:  2009-03-26       Impact factor: 4.130

Review 6.  The blood-brain barrier and methamphetamine: open sesame?

Authors:  Patric Turowski; Bridget-Ann Kenny
Journal:  Front Neurosci       Date:  2015-05-05       Impact factor: 4.677

7.  Methamphetamine enhances caveolar transport of therapeutic agents across the rodent blood-brain barrier.

Authors:  Jui-Hsien Chang; Chris Greene; Karen Frudd; Leonardo Araujo Dos Santos; Clare Futter; Benjamin J Nichols; Matthew Campbell; Patric Turowski
Journal:  Cell Rep Med       Date:  2022-01-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.